Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [21] Expression of glutathione S-transferase pi and cisplatin resistance in human ovarian cancer
    Kase, H
    Kodama, S
    Tanaka, K
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (03) : 241 - 245
  • [22] Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
    Song, Mengdi
    Cui, Mingxiao
    Liu, Kehai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 232
  • [23] Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer
    Chappell, Nicole P.
    Teng, Pang-ning
    Hood, Brian L.
    Wane, Guisong
    Darcy, Kathleen M.
    Hamilton, Chad A.
    Maxwell, G. Larry
    Conrads, Thomas P.
    JOURNAL OF PROTEOME RESEARCH, 2012, 11 (09) : 4605 - 4614
  • [24] Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
    Schmidtova, Silvia
    Kalayska, Katarina
    Gercakova, Katarina
    Cierna, Zuzana
    Miklikova, Svetlana
    Smolkova, Bozena
    Buocikova, Verona
    Miskovska, Viera
    Durinikova, Erika
    Burikova, Monika
    Chovanec, Michal
    Matuskova, Miroslava
    Mego, Michal
    Kucerova, Lucia
    CANCERS, 2019, 11 (09)
  • [25] Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells
    Yu, Xinyi
    Liu, Feng
    Zeng, Liyi
    He, Fang
    Zhang, Ruyi
    Yan, Shujuan
    Zeng, Zongyue
    Shu, Yi
    Zhao, Chen
    Wu, Xingye
    Lei, Jiayan
    Zhang, Wenwen
    Yang, Chao
    Wu, Ke
    Wu, Ying
    An, Liping
    Huang, Shifeng
    Ji, Xiaojuan
    Gong, Cheng
    Yuan, Chengfu
    Zhang, Linghuan
    Feng, Yixiao
    Huang, Bo
    Liu, Wei
    Zhang, Bo
    Dai, Zhengyu
    Wang, Xi
    Liu, Bo
    Haydon, Rex C.
    Luu, Hue H.
    Gan, Hua
    He, Tong-Chuan
    Chen, Liqun
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (03) : 957 - 971
  • [26] Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators
    Sheikhshabani, Somayeh Hashemi
    Amini-Farsani, Zeinab
    Rahmati, Shima
    Jazaeri, Ali
    Mohammadi-Samani, Marzieh
    Asgharzade, Samira
    LIFE SCIENCES, 2021, 278
  • [27] Role of ER stress on cisplatin resistance in human ovarian cancer cells
    Xu, Ye
    Yu, Huimei
    Su, Jing
    Ma, Liwei
    Xie, Qi
    Kang, Jinsong
    Li, Hongyan
    Li, Zhixin
    Sun, Liankun
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S19 - S19
  • [28] Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
    Natividad Gomez-Roman
    Fiona McGregor
    Nial J. Wheate
    Jane A. Plumb
    Journal of Ovarian Research, 8
  • [29] PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway
    Yang, Xuemei
    Zhang, Qian
    Yang, Xiaofeng
    Zhao, Minyi
    Yang, Ting
    Yao, Anmei
    Tian, Xiaofei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 511 (04) : 719 - 724
  • [30] Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer
    Xu, Xiaoli
    Zheng, Zhiguo
    Jia, Lanlan
    Suo, Shasha
    Liu, Bowen
    Shao, Tianning
    Tu, Qinqing
    Hua, Yuejin
    Xu, Hong
    ONCOLOGY LETTERS, 2018, 16 (03) : 3796 - 3804
12345